Review Article

Diagnostic Utility of CSF Tau and A 𝜷 𝟒 𝟐 in Dementia: A Meta-Analysis

Table 1

Effect size, its 95% CI, and % weight calculations for each selected study of CSF tau in Alzheimer’s disease and dementia due to other causes.

S. no.Author’s name and year Country where the studies were conducted Tau level (pg/mL) (AD and control) Effect size (pg/mL)95% CIWeight Tau level (pg/mL) (DOC and control) Effect size (pg/mL)95% CIWeight
DiseasedControlDiseasedControl
N SDN SDRMD+SEN SDN SDRMD+SE

1Arai et al. (1995) [15]Japan199193491994.5910.0080.07753.06–1066.940.005777.245.51994.568.2017.2334.43–101.970.215
2Tapiola et al. (1998) [16]Finland8152435133293140231.0045.99140.86–321.140.0154040324833293140110.0046.1719.51–200.490.030
3Galasko et al. (1998) [17]USA8266348160387167276.0057.33163.64–388.360.010744563836038716769.0049.47−27.96–165.960.026
4Andreasen et al. (1998) [18]Sweden437963821819057606.0059.78488.83–723.170.009217083821819057518.0084.44352.51–683.490.009
5Kanai et al. (1998) [19]Japan32489297.541217128272.0056.26161.73–382.270.010332671464121712850.0032.34−13.38–113.380.061
6Andreasen et al. (2001) [7]Sweden10575941718264102495.0047.27402.36–587.640.0142346128018264102197.0063.1473.25–320.750.016
7Sjögren et al. (2002) [20]Sweden1991934917342116577.0084.87410.67–743.330.004153066517342116−36.0032.76−100.21–28.210.059
8Grossman et al. (2005) [21]US17534.6303.513260.493.8274.2078.07121.18–427.220.00573207.1270.313260.493.8−53.3040.95−133.58–26.980.038
9de Jong et al. (2006) [22]The Netherlands616133263018489429.0044.79341.21–516.790.016503033073018489119.0046.3628.14–209.860.030
10Bibl et al. (2007) [23]Germany1570048015200130500.00128.40248.34–751.660.0021534028015200130140.0079.71−16.22–296.220.010
11Ravaglia et al. (2008) [24]Italy3156.332.73624.285.932.025.9620.35–43.690.9091363.540.33624.285.939.2211.2217.23–61.210.506

*Mean in diseased group, **Mean in control group and raw mean difference.